Terumo Aortic today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in Japan for the treatment of patients with complex aortic arch disease.
Thoraflex Hybrid is the global market leader in Frozen Elephant Trunk (FET) repair and has well established clinical outcomes.
Thoraflex Hybrid is a single use medical device combining a Gelweave polyester graft with a Nitinol self-expanding stent graft and is indicated for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta in cases of aneurysm and/or dissection.
Kotaro Yoshida, Senior Vice President of Asia Pacific added: “The PMDA approval of Thoraflex Hybrid is a fantastic opportunity for Terumo Aortic in Japan. This innovative hybrid device complements our open surgical graft and endovascular portfolio currently available in Japan; the approval of this device will contribute significantly in the delivery of our commitment to providing solutions for every aorta.”
Thoraflex Hybrid received CE Mark approval in 2012 and FDA approval in 2022 with more than 13,000 devices sold around the world. This device is integral to Terumo Aortic’s market-leading portfolio of surgical, endovascular and hybrid devices to treat every segment of the aorta.
About Terumo Aortic
Notes to Editors
- Terumo acquired Vascutek Ltd. in 2002 and Bolton Medical Inc. in 2017
- Terumo Aortic has over 1,250 employees around the world with manufacturing facilities in Glasgow, Scotland and Sunrise, Florida.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.